

European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)

Patients' and Consumers' Working Party Meeting 13th September 2011







Aim of this presentation

Enpr-EMA

• To introduce Enpr-EMA:

background, stakeholders, milestones, patients' role

- To discuss how possible ways to collaborate and cooperate could be initiated and established.
- Most importantly to get your feedback ③

EUROPEAN MEDICINES AGENCY

Introduction and background of Enpr-EMA

Legal basis

Enpr-EMA

European Paediatric Regulation:

"The EMA shall, with the scientific support of the Paediatric Committee, develop a European network of existing national and European networks, investigators and centres with specific expertise in the performance of studies in the paediatric population."

EUROPEAN MEDICINES AGENCY

Introduction and background of Enpr-EMA

Mission Statement:


Enpr-EMA

Enpr-EMA will facilitate studies in order to increase availability of medicinal products authorised for use in the paediatric population.

Introduction and background of Enpr-EMA

This will be achieved by:


- Fostering high quality ethical research on the safety and effectiveness of medicines for children.
- Efficient inter-network and stakeholder collaboration in order to build up the necessary competences at Community level and to avoid unnecessary duplication of studies.
- ➤ To inform parents, carers, children and young people about clinical trials and encourage their participation.
- Raising awareness among health care professionals of the need for clinical trials in all ages of children and supporting their involvement in such studies.
- Assisting and collaborating with ethics committees on issues relevant to
 research and clinical trials in children.





Introduction and background of Enpr-EMA

Organisation and structure



EUROPEAN MEDICINES AGENCY

Introduction and background of Enpr-EMA

Stakeholders

- Pharmaceutical Industry
- Patients, parents and patient organisations
- National Competent Authorities
- Ethics Committees
- > Medical devices industry
- ➤ CRO's
- Hospital pharmacists
- Laboratories and imaging centres



What has been achieved so far?

- >> Identification of existing networks
- Implementation strategy adopted by EMA Management Board (01/2008)
- $> 1^{st}$ workshop with existing networks (02/2009)
- > 2 working groups:

Enpr-EMA

WG 1: structure and operational model (06/2009)

WG 2: definition of recognition criteria (Public consultation 02/2010)

- $> 2^{nd}$ workshop with existing networks (03/2010)
- Publication of finalised recognition criteria for self-assessment (05/2010)

What has been achieved so far?

- >> 3-month period for networks to do self-assessment and publish results
- >> Self-assessment reports screening and clarifications requested
- > Publication of list of Networks members of Enpr-EMA (01/2011)
- > 3rd workshop with existing networks and industry representatives (03/2011)
- > 1^{st} Coordinating Group face to face meeting (06/2011)
 - Mission statement, Mandate, and Conflict of Interest policy agreed
 - Communication strategy: visibility and website (adopted)
- > Currently 33 networks:

Enpr-EMA

Category 1: 18

Category 2: 1

⁹ Category 3: 14

Enpr-EMA information: http://www.ema.europa.eu




11

Enpr-EMA information: http://www.ema.europa.eu

			An Agency of the European Union			
	PEAN MEDICINES AGENCY MEDICINES HEALTH Text size: A	AA	Site-wide search		GO F	
Home Find medicine	Regulatory Special topics Document search News & events Partners & network	rks Ab	bout us	Quick links	θ	
Europe & the Agency	▶ Home ▶ Partners & Networks ▶ Networks ▶ Enpr-EMA					
Regulators outside	European Network of Paediatric Research at the					
the EU	European Medicines Agency	🖂 E	imail 🗎 P	Print 🔞 Help	📀 Share	
Patients and consumers	The European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) is a network of research networks, investigators and centres with recognised expertise in performing clinical studies in children. Enpr-EMA aims to foster high-quality ethical research on quality, safety and efficacy of medicines to be used in children. It does this through networking and stakeholder collaboration with members from within and outside the European Union (EU). Enpr-EMA's main objectives are to:	R	Related information Medicines for children			
Healthcare professionals		, ⊳f	 Paediatric Committee Paediatric medicine development 			
Pharmaceutical industry		Ŀ	The network of Paediatric Networks at the EMEA implementing strategy (15/01/2008)			
International organisations	 foster high-quality, ethical research on medicines for use in children; 					
Networks ENCepp	 enable collaboration between networks and and stakeholders; co-ordinate studies relating to paediatric medicines and avoid unnecessary testing children; 	in				
▼ Enpr-EMA	 build up scientific and administrative competence at a European level; help with the recruitment of patients for clinical trials; 					
Enpr-EMA membership	promote European Commission framework programme applications.					
ETPGAH	Enpr-EMA does not perform clinical trials or fund studies or research or decide on area for paediatric research, as this is the responsibility of Member States, the European	S				
Health technology	Commission or each individual network.					

Enpr-EMA information: http://www.ema.europa.eu



Self-assessment report

Enpr-EMA

Networks should be recognised by quality of paediatric research Recognition criteria and quality standards for self-assessment elaborated 6 Criterion:

- > Research experience and ability
- » Efficiency requirements
- Scientific competencies and capacity to provide expert advice
- > Quality management
- > Training and educational capacity to build competences
- > Public involvement
- To become member of Enpr-EMA a set of minimum recognition criteria had to be fulfilled



Criterion 6: Public involvement

Enpr-EMA

- > 6.1. Involvement of patients, parents or their organisations in the protocol design.
- > 6.2. Involvement of patients, parents or their organisations in creating the protocol information package.
- > 6.3. Involvement of patients, parents or their organisations in the prioritisation of needs for clinical trials in children.
- To become member of Enpr-EMA involvement in at least one of the above items.



Suggestions for collaboration between Enpr-EMA and PCWP

- Our Aim is to increase awareness of the need to participate in paediatric trials, AND increase patient participation in protocol design, protocol information package and prioritisation of needs for clinical trials in children.
- We have a few high level suggestions BUT we need your feedback.
- To link available webpages
 - > On Enpr-EMA webpage to create a section for Patients organisations & link to their own pages?
 - > On patients organisations websites to create a link to Enpr-EMA pages?
- Active collaboration with a PCWP representative? Would you consider nominating a contact person?? Participation in Annual
- ¹⁵ workshop? CG meetings?





Collaboration between Enpr-EMA and PCWP

Thank you for your attention, Any feed back will be greatly appreciated